TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02380560

Intervention type: DEVICE
Intervention: Ultrasonographic examination
Description: An abdominal ultrasound for: Estimation of gestational age, biophysical profile (BPP), Detection of any fetal gross anomalies, Assessment of fetal growth measurement of the Amniotic Fluid Index (AFI), Detection of any abnormal placental insertion and/or uterine structural abnormalities as septate or bicornuate uterus, measuring The myometrial thickness at 4 different sites:~a) The lower uterine segment (LUS): 2cm above the reflection of the full urinary bladder (b)The anterior wall: 1cm above the maternal umbilicus. (c)Fundus: by placing the scan probe perpendicularly above the uterine fundus so that the entire curvature of the uterus is visualized.~(d)The posterior wall: through using the maternal abdominal aortic pulsation as an anatomic marker.

Intervention type: DEVICE
Intervention: Ultrasonographic examination
Description: An abdominal ultrasound for: Estimation of gestational age, biophysical profile (BPP), Detection of any fetal gross anomalies, Assessment of fetal growth measurement of the Amniotic Fluid Index (AFI), Detection of any abnormal placental insertion and/or uterine structural abnormalities as septate or bicornuate uterus, measuring The myometrial thickness at 4 different sites:~a) The lower uterine segment (LUS): 2cm above the reflection of the full urinary bladder (b)The anterior wall: 1cm above the maternal umbilicus. (c)Fundus: by placing the scan probe perpendicularly above the uterine fundus so that the entire curvature of the uterus is visualized.~(d)The posterior wall: through using the maternal abdominal aortic pulsation as an anatomic marker.

Intervention type: DEVICE
Intervention: Ultrasonographic examination
Description: An abdominal ultrasound for: Estimation of gestational age, biophysical profile (BPP), Detection of any fetal gross anomalies, Assessment of fetal growth measurement of the Amniotic Fluid Index (AFI), Detection of any abnormal placental insertion and/or uterine structural abnormalities as septate or bicornuate uterus, measuring The myometrial thickness at 4 different sites:~a) The lower uterine segment (LUS): 2cm above the reflection of the full urinary bladder (b)The anterior wall: 1cm above the maternal umbilicus. (c)Fundus: by placing the scan probe perpendicularly above the uterine fundus so that the entire curvature of the uterus is visualized.~(d)The posterior wall: through using the maternal abdominal aortic pulsation as an anatomic marker.
Study: NCT01762605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Care

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cast
Study: NCT01136382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide
Description: pMDI, inhalation, bid, 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: pMDI, inhalation, bid, 6 weeks
Study: NCT02778321

Intervention type: DEVICE
Group type: OTHER
Intervention: Uses of SpiderFlash monitor
Description: Investigators will use the SpiderFlash®, Holter monitor (technology Secure Data) to have a storage capacity enabling a registration up to 30 days with sufficient autonomy.~The data collected :~* Demographic data: age, sex, vascular risk factors, antithrombotic therapy at the entrance, history of Transient Ischemic Accident (TIA) or Cerebral infarct (CI)~* Data on the CI:~* Monitoring Results scope ICU Neurovascular.~* Presence palpitations~* Treatment influencing the rate (beta-blockers or antiarrhythmic)~* Data on cardiac monitoring:~A questionnaire evaluating the safety of SpiderFlash® will be given to the patient and the results of Holter will be communicated at the end of the recording to the blinded rhythm specialist
Study: NCT01771939

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 25-G vitrectomy and phacoemulsification
Description: 25-G vitrectomy with Internal Limiting Membrane peeling and phacoemulsification (cataract intervention)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: phacoemulsification (cataract surgery)
Description: lens extraction after phacoemulsification and intra-ocular artificial lens implantation
Study: NCT02963259

Intervention type: DEVICE
Intervention: SJM Infinity™ DBS IPG or SJM Brio™ DBS IPG system
Description: Implanted Medtronic® IPG will be explanted and replaced by a SJM Infinity™ DBS IPG or a SJM Brio™ DBS IPG system
Study: NCT01827566

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: gluten

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: gluten free flour
Study: NCT02020915

Intervention type: PROCEDURE
Intervention: lateral sphincterotomy

Intervention type: PROCEDURE
Intervention: ultrasound guided lateral sphincterotomy
Study: NCT03727620

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amoxicillin plus metronidazole
Description: patients were administered 250 mg of Flagyl and 500 mg of Dyspamox, three times a day for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: patients were administered 200 mg of Longamycine the first day and 100 mg per day for 14 days
Study: NCT04089917

Intervention type: DEVICE
Intervention: Q Aspiration Catheter
Description: The Q Aspiration Catheter is indicated for use in the removal of fresh, soft emboli and thrombi in the neurovascular system.
Study: NCT03695692

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pelvic floor exercise and connective tissue massage
Description: Pelvic floor exercises with connective tissue massage will be performed.The massage program is carried out for 18 sessions, 3 days/week in 6 weeks. The exercise program is performed every day for 6 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pelvic floor exercise
Description: The exercise program is performed every day for 6 weeks
Study: NCT03527017

Intervention type: OTHER
Intervention: Survey on Use of Tobacco Products in the General Population
Description: Face-to-face survey to estimate the prevalence of current tobacco use status in the general population of Germany.

Intervention type: OTHER
Intervention: Survey on Use of Tobacco Products in IQOS Users
Description: Online survey to describe patterns of use in adult IQOS users residing in Germany.
Study: NCT02062489

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: 20 mg(2#)/day, PO, daily
Study: NCT02593929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruxolitinib
Study: NCT04287530

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Poly-unsaturated fatty acids supplementation
Description: Daily supplementation with 6 daily PUFA (Omega-3 and Omega-6) chewable capsules from the beginning (immediately after the pre-testing session) to the end (immediately before the post-testing session) of the observation period, for a total of three months.
Study: NCT02062489

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2#/day, PO, daily
Study: NCT00875550

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Study drug titrated up or down to maintain target UMSS range.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Study drug titrated up or down to maintain target UMSS range.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Rescue medication for sedation according to UMSS scores

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Rescue medication for sedation according to UMSS scores

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Rescue medication for pain based on UMSS scores

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Rescue medication for pain based on UMSS scores

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Rescue medication for pain based on UMSS scores.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Rescue medication for pain based on UMSS scores.
Study: NCT02334722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam
Study: NCT00002601

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: 5 ug/kg daily following stem cell reinfusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Course 2 - 100 mg/m2 at an infusion rate of 25 mg/hr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Course 1 - 150 mg/m2 by continuous intravenous infusion for 96 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Course 1 - 14 gm/M2 by continuous intravenous infusion for 96 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Course 2 - 75 mg/m2 infused at a rate of 5 mg/minute

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Administered on Day 0 following high-dose chemotherapy in both courses 1 and 2
Study: NCT02365012

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midodrine
Description: Crossover intervention comparing midodrine to placebo for subjects with orthostatic intolerance
Study: NCT04298918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive oral placebo in combination with trastuzumab emtansine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Participants will receive oral venetoclax.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Participants will receive oral venetoclax.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Participants will receive oral venetoclax.
Study: NCT04287530

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Poly-unsaturated fatty acids supplementation
Description: Daily supplementation with 6 daily PUFA (Omega-3 and Omega-6) chewable capsules from the beginning (immediately after the pre-testing session) to the end (immediately before the post-testing session) of the observation period, for a total of three months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological intervention
Description: Rehabilitation protocol adopted at IRCCS E. Medea (remote intervention delivered through the Tachidino platform), delivered during four weeks, starting two months after the pre-testing session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neuropsychological intervention
Description: Rehabilitation protocol adopted at IRCCS E. Medea (remote intervention delivered through the Tachidino platform), delivered during four weeks, starting two months after the pre-testing session.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily supplementation with 6 daily Placebo (triglycerides) chewable capsules from the beginning (immediately after the pre-testing session) to the end (immediately before the post-testing session) of the observation period, for a total of three months.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Daily supplementation with 6 daily Placebo (triglycerides) chewable capsules from the beginning (immediately after the pre-testing session) to the end (immediately before the post-testing session) of the observation period, for a total of three months.
Study: NCT04039139

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind Body Intervention 1: Mind-Body-Syndrome-Therapy (MBST)
Description: Mind body techniques for Intervention 1 will be taught in lectures and group discussion sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mind Body Intervention 2
Description: Mind body techniques for Intervention 2 will be taught in lectures and group and/or individual sessions.
Study: NCT02451956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5363
Description: Dosage and Schedule : AZD5363 400mg bid 4 days on/ 3 days off of a 7 day cycle for each week
Study: NCT04298918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Description: Participants will receive intravenous (IV) trastuzumab emtansine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Description: Participants will receive intravenous (IV) trastuzumab emtansine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Description: Participants will receive intravenous (IV) trastuzumab emtansine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Description: Participants will receive intravenous (IV) trastuzumab emtansine.
Study: NCT02451956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle.
Study: NCT03265587

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT00849550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine/oxaliplatin/bevacizumab/RAD001 (XELOX-A-Ev)
Description: bevacizumab IV, capecitabine oral, oxaliplatin IV, RAD001 oral
Study: NCT04693871

Intervention type: DEVICE
Intervention: Transesophageal ultrasound
Description: Patients with nonvalvular atrial fibrillation underwent radiofrequency ablation combined with left atrial appendage closure and recovered to sinus rhythm after the operation. To study the changes of left atrial organization and function of two groups of patients with different left atrial appendage emptying speeds.

Intervention type: DEVICE
Intervention: Transesophageal ultrasound
Description: Patients with nonvalvular atrial fibrillation underwent radiofrequency ablation combined with left atrial appendage closure and recovered to sinus rhythm after the operation. To study the changes of left atrial organization and function of two groups of patients with different left atrial appendage emptying speeds.
Study: NCT03607370

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery after 12 weeks of delay after chemoradiotherapy.
Description: Surgery consists oncologic resection of the rectal cancer with total excision of the mesorectum after 12 weeks of delay after the end of chemoradiotherapy.
Study: NCT03335501

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin pump
Description: The participant's insulin pump will be used to infuse insulin

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin pump
Description: The participant's insulin pump will be used to infuse insulin

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous glucose monitoring system
Description: The Dexcom G4 Platinum will be used to measure glucose levels

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous glucose monitoring system
Description: The Dexcom G4 Platinum will be used to measure glucose levels

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 11-hour intervention with the single-hormone artificial pancreas
Description: Subjects will be admitted at IRCM at 9:30. An intravenous catheter will be inserted into an arm or a hand vein for blood sampling purposes. A cartridge containing rapid-acting Aspart or faster acting Aspart will be placed in the insulin pump. Closed-loop strategy will start at 10:00 until 21:00. A glucose sensor reading will be entered manually into the computer every 10 minutes. The computer will generate a recommendation for the basal rates of insulin delivery. Pumps' parameters will then be changed manually to implement the computer generated recommendations.~At 12:00, a lunch meal will be served. An insulin bolus will be given 15 minutes before the meal. At 17:00, a dinner meal will be served. As recommended, an insulin bolus will be given at the time of the meal. Each subject will ingest the same meals during both visits.~Venous blood samples will be obtained for the measurement of plasma glucose and insulin concentrations. Blood samples will be taken every 20 minutes.
Study: NCT00613522

Intervention type: OTHER
Intervention: polygraphic study
Description: Berlin scale will be measured. A polygraphic study will be performed to subjects with a Berlin scale \> 2.~Patients stroke characteristics will be recorded (initial severity, stroke mechanism) at baseline and stroke outcome will be evaluated at 3 months (stroke recurrence and functional outcome).~Controls will be evaluated at 3 months using a phone interview

Intervention type: OTHER
Intervention: polygraphic study
Description: Berlin scale will be measured. A polygraphic study will be performed to subjects with a Berlin scale \> 2.~Patients stroke characteristics will be recorded (initial severity, stroke mechanism) at baseline and stroke outcome will be evaluated at 3 months (stroke recurrence and functional outcome).~Controls will be evaluated at 3 months using a phone interview
Study: NCT04599439

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac magnetic resonance imaging
Description: All patients will undergo a cardiac magnetic resonance test to calculate their border zone channel (BZC) mass. This will not be used to decide further interventions, but all the patients will be treated according to standards of care.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac magnetic resonance imaging
Description: All patients will undergo a cardiac magnetic resonance test to calculate their border zone channel (BZC) mass. This will not be used to decide further interventions, but all the patients will be treated according to standards of care.
Study: NCT04383574

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28
Description: The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd..Two doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,28,and one dose of booster immunization(the third dose) with medium dosage (600SU/0.5ml) experimental vaccine 1 year after primary immunization at the schedule of day 0,28 in phaseⅠand 6 months after primary immunization at the schedule of day 0,28 in phase Ⅱ.And the second booster dose (the fourth dose) 1 year after the second dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28
Description: The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd..Two doses of high dosage (1200SU/0.5ml) experimental vaccine at the schedule of day 0,28,and one dose of booster immunization(the third dose) with medium dosage (1200SU/0.5ml) experimental vaccine 1 year after primary immunization at the schedule of day 0,28 in phaseⅠand 6 months after primary immunization at the schedule of day 0,28 in phase Ⅱ.And the second booster dose (the fourth dose) 1 year after the second dose.
Study: NCT01864226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5545965
Description: Multiple ascending doses
Study: NCT04383574

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Two doses of placebo at the schedule of day 0,28
Description: The placebo was manufactured by Sinovac Research \& Development Co., Ltd., Two doses of placebo at the schedule of day 0,28,and one dose of booster immunization with placebo 1 year after primary immunization at the schedule of day 0,28 in phaseⅠand 6 months after primary immunization at the schedule of day 0,28 in phase Ⅱ.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28
Description: The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd..Two doses of low dosage (300SU/0.5ml)experimental vaccine at the schedule of day 0,28,and one dose of booster immunization with low dosage (300SU/0.5ml) experimental vaccine 6 months after primary immunization at the schedule of day 0,28 in phase Ⅱ.
Study: NCT03593512

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: Bilateral deep brain stimulation of the pedunculopontine nucleus
Study: NCT03421717

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Chitosan brush
Description: If inflammation (Bleeding on probing) and deep pockets (4 mm or more) is present at the control - maintenance is performed according to allocation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chitosan brush
Description: If inflammation (Bleeding on probing) and deep pockets (4 mm or more) is present at the control - maintenance is performed according to allocation
Study: NCT00520988

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of telephone-based Interactive Voice Recognition system
Description: Use of telephone-based Interactive Voice Recognition system, for reporting of health information and blood pressure measurements
Study: NCT03137251

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TENS 1
Description: A portable TENS unit will be used by the principal investigator to apply the experimental intervention. Two pairs of electrodes measuring 5 x 9 cm will be fixed on the paravertebral regions of the participants of the experimental group using hypoallergenic surgical tape. Two paired electrodes will be placed 1 cm laterally on either side of the spine at the T10 to L1 and S2 to S4 levels.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS 1
Description: A portable TENS unit will be used by the principal investigator to apply the experimental intervention. Two pairs of electrodes measuring 5 x 9 cm will be fixed on the paravertebral regions of the participants of the experimental group using hypoallergenic surgical tape. Two paired electrodes will be placed 1 cm laterally on either side of the spine at the T10 to L1 and S2 to S4 levels.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS 2
Description: An intervention similar to arm 1 will be performed but with different doses.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS 2
Description: An intervention similar to arm 1 will be performed but with different doses.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo TENS
Description: An intervention similar to arm 1and 2 will be performed but,in this case, it is a sham device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo TENS
Description: An intervention similar to arm 1and 2 will be performed but,in this case, it is a sham device.
Study: NCT05978726

Intervention type: DRUG
Intervention: Dual antiplatelet therapy with aspirin and either ticagrelor or clopidogrel
Description: Patients with acute myocardial infarction randomly received dual antiplatelet therapy with with aspirin 100mg daily and either ticagrelor 90mg twice daily or clopidogrel 75mg once daily for at least 9 months after PCI as needed.